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Abstract
LIV-1, a zinc transporter, is an effector molecule downstream from soluble growth factors. This protein has been shown to
promote epithelial-to-mesenchymal transition (EMT) in human pancreatic, breast, and prostate cancer cells. Despite the
implication of LIV-1 in cancer growth and metastasis, there has been no study to determine the role of LIV-1 in prostate
cancer progression. Moreover, there was no clear delineation of the molecular mechanism underlying LIV-1 function in
cancer cells. In the present communication, we found increased LIV-1 expression in benign, PIN, primary and bone
metastatic human prostate cancer. We characterized the mechanism by which LIV-1 drives human prostate cancer EMT in
an androgen-refractory prostate cancer cells (ARCaP) prostate cancer bone metastasis model. LIV-1, when overexpressed in
ARCaPE (derivative cells of ARCaP with epithelial phenotype) cells, promoted EMT irreversibly. LIV-1 overexpressed ARCaPE
cells had elevated levels of HB-EGF and matrix metalloproteinase (MMP) 2 and MMP 9 proteolytic enzyme activities, without
affecting intracellular zinc concentration. The activation of MMPs resulted in the shedding of heparin binding-epidermal
growth factor (HB-EGF) from ARCaPE cells that elicited constitutive epidermal growth factor receptor (EGFR)
phosphorylation and its downstream extracellular signal regulated kinase (ERK) signaling. These results suggest that LIV-
1 is involved in prostate cancer progression as an intracellular target of growth factor receptor signaling which promoted
EMT and cancer metastasis. LIV-1 could be an attractive therapeutic target for the eradication of pre-existing human
prostate cancer and bone and soft tissue metastases.
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Introduction
LIV-1, a cell surface protein and a candidate mediator of the
growth factor-elicited signaling molecule, has been associated with
several important biologic processes by serving as a transporter for
zinc and other ions [1,2,3,4,5]. As a prototype of the LIV-1
subfamily of ZIP metal transporters [5,6], LIV-1 shares secondary
structure with ZIP transporters and may have the ability to
transport metal ions. LIV-1 was shown to be a mediator
downstream from signal transducer and activator of transcription
3 (STAT3) and Snail, cooperating with Snail in the repression of
epithelial marker E-cadherin (E-cad) gene transcription [7]. LIV-1
wasalsoshowntobeaninteractingpartnerfortheestrogenreceptor
(ER) in hormone-sensitive tissues [3,8]. In the ER-positive ZR-75-1
breast cancer cell line, LIV-1 transcription is induced by estrogens
[9]. In breast tumors, LIV-1 expression is associated with ER status
[10,11], and is positively correlated with the spread of cancer to
regional lymph nodes [12]. In cervical cancer, expression of LIV-1
was shown to be higher in tumor than normal tissues; RNAi-
mediated suppression of LIV-1 significantly inhibited cell prolifer-
ation, colony formation, and reduced the migratory and invasive
ability of the HeLa cells [13]. LIV-1 has also been reported to be
elevated in clinical pancreatic carcinoma and induced EMT in
pancreatic cancer cells [14]. In zebrafish, LIV-1 is essential for the
nuclear localization of Snail, a master transcription factor
promoting epithelial to mesenchymal transition (EMT), causing
migration of gastrula organizing cells [15]. LIV-1 thus is an
obligatory co-factor regulating EMT-associated genes [14,15,16].
The potential diagnostic and prognostic value of LIV-1 in
human prostate cancer has not been investigated. Since zinc plays
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27720important roles in the maintenance of prostate epithelial cell
homeostasis [17], and Snail is a key transcription factor controlling
prostate cancer cell EMT [18,19,20], LIV-1 may be an active
participant in the promotion of EMT during prostate cancer
progression and bone metastasis. In this study, we determined the
level of LIV-1 in human prostate cancer cell lines and clinical
tissue specimens to define the relationship between LIV-1 and
prostate cancer progression and metastasis. The ARCaP human
prostate cancer progression cell model was used to evaluate the
role of LIV-1. Our study found that LIV-1 overexpression
promotes prostate cancer cell EMT and facilitates its metastasis
to bone and soft tissues. Further mechanistic investigation revealed
that LIV-1 overexpression could upregulate HB-EGF and MMP2
and MMP9 expression. The latter could enzymatically cleave
membrane-bound HB-EGF, to produce soluble HB-EGF that
constitutively activated EGFR via increased EGFR phosphoryla-
tion and its downstream ERK signaling. The results from this
study demonstrate that abnormally enhanced LIV-1 expression is
a marker of prostate cancer progression, and activated LIV-1 is
responsible for constitutive activation of EGFR which drives
EMT. LIV-1 could be an attractive new therapeutic target for the
inhibition of prostate cancer EMT and bone and soft tissue
metastases.
Materials and Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines, and was approved by the Institutional
Animal Care and Use Committee (IACUC) of Emory University
School of Medicine (Permit number 254-2008).
Cell lines and cell culture
Human prostate cancer ARCaPE and ARCaPM cells (derivative
cells of ARCaP with epithelial and mesenchymal phenotype,
respectively) were established in our laboratory [21]. The cells
were cultured in T-medium (Invitrogen, Carlsbad, CA) supple-
mented with 5% fetal bovine serum (FBS, Atlanta Biologicals,
Lawrenceville, GA). Human embryonic kidney HEK293 cells
were obtained from American Type Culture Collection (Manassas,
VA) and cultured in DMEM (Invitrogen) supplemented with 10%
FBS. RPMI-1640 was purchased from Invitrogen (Carlsbad, CA).
All the culture media were supplemented with penicillin (100 U/
ml) and streptomycin (100 mg/ml). Cell cultures were maintained
at 37uC in a humidified atmosphere supplemented with 5% CO2.
Antibodies and reagents
Polyclonal rabbit antibody against LIV-1 was generated in our
laboratory. Rabbits were immunized by standard immunization
protocol with conjugated peptide KLH-CPDHDSDSSGKDPRNS,
corresponding to residues 146-161 of the LIV-1 protein (GenBank
accession number NM_012319). Blood was taken 2 weeks after the
fourth boost and IgG were purified and tested for specific immune
reactivity. Polyclonal antibody to E-cadherin (E-cad), monoclonal
antibody to vimentin and phospho-EGFR antibody were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal
antibody to N-cadherin (N-cad) and EGFR were from BD
Transduction Laboratories (San Diego, CA). Antibodies to p44/42
MAP kinase and the phosphorylated isoforms were from Cell
Signaling Technology (Danvers, MA). Monoclonal antibody to b-
actin was from Sigma-Aldrich (St. Louis, MO).
Insulin-like growth factor-1 (IGF-1) and transforming growth
factor-b1 (TGF-b1) were purchased from Diagnostic Systems
Laboratories (Webster, TX). Epidermal growth factor (EGF) was
from R&D Systems (Minneapolis, MN). Tyrphostin AG1478,
U0126 and MMP2/9 inhibitor III were obtained from Alomone
labs (Jerusalem, Israel), Cell Signaling Technology (Danvers, MA),
and Calbiochem (Darmstadt, Germany), respectively.
Transfection
Full-length coding region for human LIV-1 cDNA was cloned
and confirmed by DNA sequencing. The cDNA was then cloned
downstream from a cytomegalovirus early promoter in the
mammalian expression vector pcDNA3.1/V5-His (Invitrogen).
HEK293 and ARCaPE cells were seeded at 3610
5 cells per well in
6-well plates 24 hours before transfection. The cells were
transfected with 4 mg of the LIV-1 expression construct using
8 ml Lipofectamine 2000 (Invitrogen). To isolate clones stably
overexpressing LIV-1, transfected ARCaPE cells were treated with
G418 (600 mg/ml) 2 days after the transfection. Four individual
clones overexpressing LIV-1 protein (LIV#8, #12, #14 and #17)
and two clones transfected with control vector (con1 and con2)
were used for the studies.
siRNA knockdown
LIV-1 siRNA was purchased from Invitrogen. ARCaPM cells
were seeded at 3610
5 cells per well in 6-well plates for 24 hrs. The
cells were transfected with 2.5 mlo f2 0mM LIV-1 siRNA or equal
amount of universal control siRNA, using 8 ml Lipofectamine
2000 per well. Cells were harvested and assayed 48 hours after
transfection.
Semiquantitative expression analysis with reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cultured cells using the RNeasy
Mini kit (Qiagen, Valencia, CA). From each sample, equal amount
of RNA (2 mg) was used in first–strand cDNA synthesis reaction
with the Superscript First-Strand cDNA Synthesis kit (Invitrogen).
Equal volumes of cDNA (3 ml) from each reaction were used for
PCR analysis using gene-specific oligonucleotide primer pairs: 59-
GCAATGGCGAGGAAGTTATCT-39 and 59-CTATTGTCT-
CTAGAAAGTGAG-39 for LIV-1; 59-TGCCCAGAAAATGA-
AAAAGG-39 and 59-GTGTATGTGGCAATGCGTTC-39 for
E-cad; ; 59-CCATCACTCGGCTTAATGGT-39 and 59-GAT-
GATGATGCAGAGCAGGA-39 for N-cad; 59-CGAAAGGCC-
TTCAACTGCAAAT-39 and 59-ACTGGTACTTCTTGACA-
TCTG-39 for Snail; 59-TGCCCGGCGGAATCTCCTGA-39
and 59-GATGCAGGAGGGAGCCCGGA-39 for HB-EGF; 59-
GCTGTCTGCGTGGTGGTGCT -39 and 59- TGGTGTGG-
TGGGTCCAGGGC -39 for EGF; and 59-TTAGCACCC-
CTGGCCAAGG-39 and 59-CTTACTCCTTGGAGGCCATG-
39 for GAPDH. The reactions were initiated with a 4-minute
incubation at 94uC, followed by 30 cycles at 94uC for 30 seconds,
55uC for 30 seconds, and 72uC for 1 minute. The reaction was
completed with a 7-minute extension at 70uC for 7 minutes. PCR
products were visualized after electrophoresis through a 1.2%
agarose gel and stained by ethidium bromide (0.5 mg/ml).
Western blotting
Cells at 80% confluence were lysed in a whole-cell lysis buffer as
previously reported [22]. The lysates were incubated on ice for
30 minutes and centrifuged at 10,000 rpm at 4uC for 10 minutes.
From each sample, 35 mg protein in the supernatant was resolved
by SDS-PAGE and blotted onto a nitrocellulose membrane
(BioRad, Hercules, CA), which was blocked in 5% skim milk in
PBST (137 mM NaCl, 12 mM phosphate, 2.7 mM KCl, and
0.1% Tween 20) at room temperature for 20 minutes and
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membranes were then washed three times in PBST and incubated
with horseradish peroxidase-conjugated secondary antibody for 1
hour at room temperature. After five washings in PBST, specific
signals were detected by incubating the membrane with ECL
reagent (Amersham-Pharmacia Biotech, Piscataway, NJ).
Measuring intracellular zinc concentration
Two methods were used to determine intracellular zinc
concentration. To prepare samples for assaying total intracellular
zinc by the inductively coupled plasma mass spectrometry (ICP-
MS), cultured cells at 80% confluence were trypsinized and
washed in PBS, and then incubated in 300 ml of 70% nitric acid at
37uC for 2 hours. The cells were then placed in 2% nitric acid and
subjected to ICP-MS with a Varian instrument. A standard curve
was generated with serial dilutions of zinc instrument standards.
To prepare samples for assaying intracellular labile zinc by
fluorometric method, cells were seeded at 3610
5 cells per well in
6-well plates the day before measurement. The cells were loaded
with 2 mM of FluoZIN-3 AM (Invitrogen) for 1 hour in Opti-
MEM containing 0.02% Pluronic F127 (Invitrogen). After washing
in PBS, the loaded cells were incubated in indicator-free Opti-
MEM for 30 minutes. Fluorescence of the FluoZin-3 was
measured using a PE Victor
3 V plate reader.
Scratch wound healing assay
ARCaPM cells transfected transiently with LIV-1 siRNA or
universal siRNA control were used to determine migratory
behavior. The cells were gently and slowly scratched with a
10 ml pipette tip across the center of the well 48 hours after
transfection. After scratching, the well was gently washed twice
with medium to remove the detached cells. The well was
replenished with fresh medium. Photos were taken 48 hrs after
scratching. Multiple views of each well were documented, and
three independent experiments were performed.
Trans-well migration and invasion assays
To perform a trans-well migration assay, 2.5610
4 cells in the
top chamber of 24-well transwell plates of 8 mm pore size (BD
Biosciences) were incubated for 16 hours in complete medium that
was added to the bottom chamber. Cells were then fixed with
formalin and stained with 0.5% crystal violet. The non-migrated
cells inside the chamber were removed by swabbing. Crystal violet
for the migrating cells was solubilized into Sorenson’s buffer
(0.1 M sodium citrate and 50% ethanol, pH 4.2) and measured for
absorbance at OD590. The invasion assay was performed using BD
BioCoat Matrigel invasion chambers (BD Biosciences; 8-mm pore
size). The same procedures described above were used, except the
filters were pre-coated with 100 ml Matrigel at a 1:4 dilution in
RPMI-1640.
Assessment of tumorigenic and metastatic potentials
The functional roles of LIV-1 in prostate tumor formation and
metastasis were assessed as reported previously [23]. To assess
local tumor growth, 4-week-old athymic male mice (Ncr-nu/nu,
National Cancer Institute, Frederick, MD) were inoculated
subcutaneously with ARCaPE cells (1610
6 in 50 ml PBS) stably
transduced with LIV-1. Tumor dimension was measured with a
caliper at days 23, 32, 43, and 50 after injection, and tumor
volume was calculated as length 6width 6height 60.5236 [24].
To assess cancer metastases, athymic male mice were inoculated
intracardiacally with ARCaPE cells (2610
6 in 100 ml PBS) stably
transduced with LIV-1 to the left ventricles. Animals were
observed for 4 months for development of metastatic lesions.
Bone metastases were recorded by X-ray radiography and soft
tissue metastases were confirmed by histopathology.
Immunohistochemistry (IHC) of tissue microarray (TMA)
The normal and diseased prostate tissues analyzed were from: 1)
One custom-made TMA with normal prostate tissues from 4
healthy men; matched cancer, benign, and PIN tissues from 12
prostate cancer cases; matched benign and cancer tissues from 11
cases; matched PIN and cancer from 1 case; benign prostatic
hyperplasia (BPH) from 2 cases; and prostate cancer bony
metastasis from 3 prostate cancer cases. 2) One custom-made
TMA consisted of 47 bone metastasis tissues from 11 prostate
cancer patients. 3) Four TMAs each containing 66 cases of
prostate cancer and benign prostate disorders (US Biomax.
Rockville, MD).
The IHC protocol for evaluating gene expression has been
reported [22]. Briefly, specimens were deparaffinized, rehydrated
and subjected to antigen retrieval. After endogenous peroxidase
blocking, the specimens were incubated with primary antibody at
4 ˚C overnight, followed by a 30-minute incubation with DakoCy-
tomation EnVision+ HRP reagent. Signals were detected by
adding diaminobenzidine as chromogen and counterstaining by
hematoxylin. Pre-immunization rabbit serum served as negative
control. IHC staining was scored by two investigators indepen-
dently based on four staining intensities from 0 to +++ as
previously reported [22].
Gelatin zymography
All gelatin zymography reagents were purchased from Invitro-
gen. Cells were cultured in serum-free RPMI1640 medium for
24 hours and conditioned medium was collected. Protein in the
medium was concentrated with an AmiconUltracel 30 KDa filter
(Millipore, Billerica, MA). Equal amounts of protein (10 mg/sample)
were mixed with 26Novex Tris-Glycine SDS sample buffer, and
fractionated on a 10% gelatin gel under non-reducing conditions.
The gel was then incubated at 37uC in renaturing buffer for
30 minutes and in developing buffer for 30 minutes. Finally, the gel
was stained in SimplyBlue Safestain, and bands representing the
gelatinase activity of MMP2 and MMP9 were quantified.
Enzyme-linked immunosorbent assay (ELISA) for HB-EGF
Cells were cultured in serum-free RPMI1640 medium for
24 hours. Conditioned medium was collected and analyzed for
HB-EGF concentration with the Human HB-EGF Duoset ELISA
kit (R&D Systems), following the manufacturer’s recommended
protocol. Each sample from three independent experiments was
assayed in triplicate.
Statistical analysis
To analyze the potential association of LIV-1 protein expression
and prostate cancer progression from normal/benign, prostatic
intraepithelial neoplasia (PIN), localized primary cancer, to bone
metastasis,theLIV-1expressionlevelwasdividedintotwocategories:
staining intensity of high (3) vs. medium to null (2 to 0, respectively).
The Kruskal Wallis non-parametric test was used to determine the
equality of population medians among prostate cancer progressions
of normal/benign, PIN, primary cancer, and bone metastasis. This
test is equivalent to the parametric ANOVA test used when there are
more than two groups being compared. The Mann-Whitney non-
parametric test was applied to determine the equality of population
medians between two cancer progressions, 1) bone metastasis vs.
localized cancer;and 2)bone metastasis vs.benign, PIN, and primary
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when there are only two groups being compared. Logistic regression
was used to model the relationship between binary Gleason scores
whichweredividedintobinaryvariablesofwell-differentiated(GI#6)
vs. moderate to poorly differentiated (GI$7) prostate cancer. SAS
and Minitab were used in this analysis.
Results
The human prostate cancer ARCaP cells established in our
laboratory [21] can be readily promoted to undergo EMT in
response to soluble factors and matrix proteins present in the
tumor microenvironment [20,25,26,27]. To elucidate the molec-
ular mechanism regulating EMT, epithelial ARCaPE was
analyzed for differential gene expression in response to soluble
factors, in comparison to its ARCaPM counterpart which displayed
a mesenchymal phenotype. LIV-1 was one of the differentially
expressed genes identified [27]. In the current study, we
investigated the role of LIV-1 in regulating EMT in ARCaP cells
to assess the possible mechanism of LIV-1 action in the promotion
of prostate cancer bone and soft tissue metastases.
LIV-1 was involved in promoting EMT in the ARCaP cell
model
We previously reported that ARCaPE cells underwent EMT
when treated with soluble factors including IGF-1, EGF, TGF-b1
Figure 1. LIV-1 is a mediator in ARCaPE cell EMT. The role of LIV-1 was assessed by its changed expression during EMT. A, ARCaPE cells were
treated for 48 hours with growth factors to induce EMT. RT-PCR and Western blotting were used to show increased LIV-1 expression (left panel), and
the dose responsiveness of the expression (right panel). B, Western blotting was used to confirm EMT-like expressional changes in the treated
ARCaPE cells. C, mesenchymal cell-like ARCaPM cells were subjected to siRNA knockdown for LIV-1 expression for 48 hours. RT-PCR and Western
blotting were used to detect expressional changes reflecting reversal of EMT in the treated cells. D, Scratch wound healing and transwell invasion
assays were used to determine migratory and invasive behavior in siRNA treated ARCaPM cells. * indicates statistical significance compared to the
con1 control clone (P,0.05). E, ARCaPE cells were transfected with LIV-1 expression construct. RT-PCR and western blotting were performed 48 hours
after transfection to detect expressional changes reflecting EMT-like events. GAPDH served as an internal control for RT-PCR reactions, and b-actin
was used as a loading control in Western blotting.
doi:10.1371/journal.pone.0027720.g001
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when ARCaPE cells were treated with either TGF-b1 or IGF-1, an
induction of LIV-1 expression was detected by both RT-PCR and
Western blotting analyses (Figure 1A). When different concentra-
tions of IGF-1 were added to the induction medium, the
responsiveness of LIV-1 expression was found to be dose-
dependent (Figure 1A). IGF-1-induced LIV-1 expression in
ARCaPE cells occurred concomitantly with a switch of cell
morphology and gene expression toward mesenchymal phenotype,
i.e., the loss of tightly adhesive polarized epithelial morphology to
become loosely dispersed fibroblastic cells with increased expres-
sion of N-cad and vimentin but decreased expression of E-cad, a
hallmark retained by polarized epithelial cells (Figure 1B).
Activated LIV-1 expression seemed to occur concurrently with
the transition of ARCaPE to ARCaPM, an ARCaP mesenchymal
variant [21].
To define the role of LIV-1 in mediating EMT, we transiently
reduced the LIV-1 level in the mesenchymal-like ARCaPM cells by
siRNA knockdown. ARCaPM cells treated with specific LIV-1
siRNA showed markedly reduced LIV-1 transcripts (Figure 1C).
Importantly, the treated cells showed decreased expression of
mesenchymal markers N-cad and Snail, but increased expression
of the E-cad gene in both RT-PCR and Western blotting analyses
(Figure 1C). In addition, ARCaPM cells treated with specific LIV-1
siRNA exhibited much reduced migratory and invasive ability in
scratch wound-healing and transwell invasion assays (Figure 1D).
These results suggested that LIV-1 expression is associated with
EMT and decreased LIV-1 expression leading to mesenchymal to
epithelial transition (MET), a reversal of EMT. The presence of
LIV-1 appeared to be required for the maintenance of a
mesenchymal phenotype.
We next examined whether elevated LIV-1 in the epithelial-like
ARCaPE cells would be sufficient to initiate EMT, as assessed by
molecular analyses. Following transient transfection with a LIV-1
expression construct, ARCaPE cells were examined by both RT-
PCR and western blotting assays for the expression of EMT-
associated markers. The transfected ARCaPE cells displayed
markedly increased LIV-1 expression (Figure 1E), accompanied
by increased N-cad and Snail but a decreased E-cad expression.
These expressional changes were in agreement with those seen in
growth factor-elicited EMT (Figure 1B). Results from LIV-1
siRNA knockdown and LIV-1 overexpression studies in ARCaPM
and ARCaPE cells suggested that LIV-1 serves a key regulator of
EMT in human prostate cancer cells.
Production and characterization of polyclonal antibodies
to human LIV-1
To evaluate if LIV-1 expression is associated with clinical
progression of human prostate cancer, we raised polyclonal
antibodies by immunizing rabbits with a KLH-conjugated LIV-1
Figure 2. Validation of the antibodies to LIV-1. The produced antibodies to LIV-1 were subjected to validation for specificity. A, HEK293 cells
transiently transfected with the LIV-1 expression construct were subjected to Western blotting analysis with the antibodies to LIV-1 (upper panel).
Antibody specificity was determined by pre-absorbing the antibody with the immunizing peptide (middle panel). B, ARCaPE cells were transiently
transfected with the LIV-1 expression construct to overexpress LIV-1 and ARCaPM cells with the specific siRNA to suppress LIV-1 expression. In the
upper 2 panels, Western blotting was performed 48 hours later with the antibodies to LIV-1. In the lower 2 panels, these cells were examined by RT-
PCR to confirm the LIV-1 expression. b-actin was used as control in Western blotting and GAPDH was used as control for RT-PCR analysis. C, IHC was
conducted to further confirm LIV-1 Ab specificity in ARCaPE cells transiently transfected with the LIV-1 expression construct and ARCaPM cells
transiently transfected with the specific siRNA (200 6).
doi:10.1371/journal.pone.0027720.g002
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blotting of the whole-cell extracts from cells overexpressing
exogenous LIV-1. From the HEK293 cells transiently transfected
with LIV-1, we observed a single immune-reactive LIV-1 protein,
at 110 kDa (Figure 2A). Since the calculated molecular weight of
LIV-1 protein is 90 kDa [5], the differential 20 kDa between the
detected and the predicted sizes was likely attributed to N-linked
glycosylation of the LIV-1 protein, as previously reported [5].
Importantly, the signal detected by the LIV-1 antibodies was
abolished when the antibodies were pre-adsorbed with the LIV-1
peptide used in immunization. In addition, increased signal
intensity was detected in ARCaPE cells transiently transfected
with the LIV-1 expression construct, while a reduction of the
signal was seen in ARCaPM cells treated with a transient LIV-1
knockdown vector in both Western blotting and IHC assays
(Figure 2B and 2C). These results indicated that the LIV-1
antibodies produced could detect specifically LIV-1 protein, which
was modified in the cell lines tested.
Stable LIV-1 overexpression induced EMT in ARCaPE cells
Following transient knockdown of LIV-1 in ARCaPM cells, an
expected reversal of the mesenchymal fibroblastic cell shape to
epithelial morphology was observed. These morphologic switches
were readily detectable by gene expression changes (Figure 1C). In
contrast, transiently overexpressing LIV-1 in ARCaPE cells did not
induce mesenchymal morphologic transition, despite concerted
expressional changes indicative of EMT (Figure 1E). We suspected
that the lack of morphologic changes may be attributable to the
nature of the transient transfection. Accordingly, stable ARCaPE
clones were established to evaluate whether LIV-1 is a critical
regulator associated with morphologic as well as expressional and
behavioral transition from an epithelial to a mesenchymal
phenotype.
We isolated 4 ARCaPE clones (LIV#8, 12, 14 and 17) stably
expressing high levels of LIV-1 protein, as detected by Western
blotting (Figure 3A). Two control clones (con1 and con2) were also
isolated from transfection with the control vector. The ones
overexpressing LIV-1 showed typical EMT-like expressional
changes, with decreased E-cad expression but increased N-cad
and Snail expressions (Figure 3A). Significantly, all the clones
showed markedly changed cellular morphology: instead of the
small cell size with cobblestone-like shape with tightly arranged
intercellular contact typical of the epithelial cell-like ARCaPE, all
four clones adapted remarkably altered morphology displaying a
Figure 3. LIV-1 overexpression induced EMT. ARCaPE clones overexpressing LIV-1 displayed EMT-like changes in gene expression, cellular
morphology and behavior. A, all four LIV-1 overexpressing ARCaPE clones showed EMT-like expressional changes as detected by Western blotting,
while the two vector control clones (1 and 2) retained an epithelial cell-like expression profile. B, cellular morphology of the LIV-1 overexpressing cells
showed marked changes from the control clones (2006). C, LIV-1 overexpressing cells (LIV#8 and LIV#14 were compared with vector control clones
1 and 2 and parental ARCaPE and ARCaPM cells for altered migratory capability in transwell assays. Each result is the mean 6 standard deviation of a
triplicate assay. D, the LIV-1 overexpressing #8 and #14 clones were compared with vector control clones 1 and 2 and parental ARCaPE and ARCaPM
cells for altered invasiveness. * indicates statistical significance compared to the con1 control clone (P,0.05).
doi:10.1371/journal.pone.0027720.g003
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mal cell morphology (Figure 3B). The morphologic transition was
permanent and irreversible, persisting after more than 30 passages
in continuous culture, while the two vector-transfected clones
remained epithelial cell-like. It seems that stable LIV-1 overex-
pression could bring forth both morphologic and biochemical
EMT transition. LIV-1 is thus a potent promoter of EMT in
ARCaPE cells.
The effects of LIV-1 on behavioral changes were assessed for its
promotion of cell migration and invasion in Boyden chamber
assays. While the control neo transfected ARCaPE clones showed
similar migration and invasion capabilities closely mimicking those
of the parental ARCaPE cells, repeated assays revealed that LIV-1
overexpression conferred significantly increased migratory capa-
bility (Figure 3C) and invasive potential to penetrate extracellular
matrices (Figure 3D). Taken together, these data support the
notion that increased LIV-1 levels promote the motility and
invasive behaviors of prostate cancer cells.
LIV-1 overexpression promoted prostate tumor
formation and distant metastases in vivo
We examined the role of LIV-1 stably expressed in ARCAPE
cells in modulating subsequent tumorigenic and metastatic
behaviors in mice. We compared local and distant metastatic
growth of ARCaPE tumors by subcutaneous and intracardiac
tumor cell inoculation protocols as described previously [21,23].
Following subcutaneous implantation, LIV-1 overexpressing
clones induced a similar incidence of tumor formation to the
vector-transfected controls, each group having 6 tumors from a
total of 8 inoculations. Nonetheless, LIV-1-overexpressing clones
formed significantly larger tumors than the control clones when
the tumors were measured at 43 and 50 days after inoculation
(Figure 4). Due to the large tumor burden in the LIV-1 transfected
experimental group, these studies were terminated at day 50. At
this time, the average tumor size of LIV-1-overexpressing clones
was 3 - 5 times larger than that of the control clones, with no
evidence of distant metastases.
We then used intracardial inoculation to evaluate the metastatic
fate of LIV-1 overexpressing ARCaPE cells. Four months after
intracardiac administration, the mice inoculated with LIV-1
overexpressing ARCaPE clones presented with significantly
elevated incidence of tumors at multiple organ sites, including
the bone and soft tissues of lymph nodes, adrenal glands and lung,
compared to vector-transfected controls (Table 1). Among the
seven animals inoculated with LIV-1-overexpressing ARCaPE
clone 8, two were found to have multiple bone metastases, both in
tibial, mandibular, and spinal bones (Figure 5A), while another
four mice were found to harbor soft tissue tumors of the adrenal
glands and the lung (Figure 5B). All the tumors were confirmed by
histopathologic analysis. In a parallel study, five of the nine
animals inoculated with LIV-1-overexpressing ARCaPE clone 14
were found to bear bone metastasis. In sharp contrast, intracardiac
inoculation of vector-transfected controls did not produce any
detectable metastases in bone or soft tissues (Table 1). This series
of assays demonstrated that by increasing the migratory and
invasive behaviors of prostate cancer cells, LIV-1 promoted
metastatic growth of prostate cancer cells to the bone and the soft
tissues.
Enhanced LIV-1 expression in clinical prostate cancer
specimens
In order to examine the correlation between LIV-1 expression
and cancer malignancy, we first assessed LIV-1 expression in
different prostate cancer cell lines. We chose the isogenic LNCaP
series (LNCaP, C4-2 and C4-2B) and ARCaP series (ARCaPE,
ARCaPM and ARCaPM2) cell lines. Both series range from low
potential to high potential for metastasis. C4-2, C4-2B, ARCaPM
and ARCaPM2 specifically metastasize to bone. We found that
LIV-1 expression correlated with the metastatic potential of these
isogenic cell models. LIV-1 expression is higher in the bone
metastatic cell lines than non- or low-metastatic cells such as
LNCaP and ARCaPE (Figure 6A).
Based on findings in ARCaP cells where LIV-1 was shown to
induce EMT and prostate cancer local growth and distant
metastases and LIV-1 expression in different cancer cell lines,
we sought to demonstrate the clinical relevance of these findings
by performing a series of IHC assays. A LIV-1 polyclonal antibody
established by our laboratory was used to detect LIV-1 status in
clinical specimens on two custom-made TMAs of normal, benign/
Table 1. LIV-1 promotes prostate cancer cell metastasis.*
Clones Incidence of metastasis Sites of metastasis
con1 0/6 N/A
con2 0/6 N/A
LIV#8 6/7 (86%) 2, adrenal gland
2, lung
1, leg bone
1, jaw and spine
LIV#14 5/9 (56%) 2, leg bone
1, iliac bone
1, femur
1, zygomatic and spine
*LIV-1-overexpression clones (LIV#8 and LIV#14) and vector-transfected clones
(con1 and con2) were intracardially inoculated to athymic mice. Incidence and
sites of metastasis were followed up to 4 months by necropsy and
histopathologic confirmation.
doi:10.1371/journal.pone.0027720.t001
Figure 4. LIV-1 overexpression promoted subcutaneous tumor
growth. Upon subcutaneous inoculation, the two ARCaPE clones
overexpressing LIV-1 (LIV8 and LIV14) were compared with vector
control clones (con1 and con2) for tumor formation in athymic mice.
Growth of the tumors at day 23, 32, 43, and 50 is shown. Each result
represents the mean 6 standard deviation of six tumors. An asterisk
indicates statistical significance compared to the con1 control clone
(P,0.05).
doi:10.1371/journal.pone.0027720.g004
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commercial TMAs of benign and prostate cancer specimens.
These TMAs represented a total of 344 prostate specimens
including bone metastasis specimens from 14 patients. Results
from a Kruskal Wallis non-parametric test showed a remarkable
positive correlation of LIV-1 expression with disease progression
from normal, benign, PIN, and primary to bone metastasis
(P,0.001). Figure 6B shows representative IHC images of
increased LIV-1 expression in human prostate specimens from
benign to bone metastasis. Significant differences were also found
when LIV-1 expression was subjected to Mann-Whitney non-
parametric test between either bone metastasis versus localized
cancer (p=0.002) or bone metastasis versus normal/benign, PIN,
primary cancer and metastasis (p=0.001) (Figure 6C). There was,
however, no positive correlation between LIV-1 expression in
well-differentiated (GI#6) and moderate to poorly-differentiated
(GI$7) prostate cancers by Logistic regression test.
LIV-1 overexpression activated EGFR and downstream
ERK signaling
We next explored the mechanism by which LIV-1 promoted
prostate cancer EMT, progression and metastasis. We examined
the phosphorylation status of AKT, p38, JNK, Smad, NF-kB, b-
catenin and ERK because these regulatory proteins were shown to
be altered by a soluble growth factor, b2-M, which also promoted
EMT and LIV-1 expression [25,26,27]. In this study, we observed
that ERK signaling was significantly activated (Figure 7A). Since
ERK was frequently activated by growth factor receptor signaling,
we examined specifically the phosphorylation status of IGF-1R,
TGF-b receptor and EGFR proteins. This series of analyses
revealed specifically increased EGFR phosphorylation in the LIV-
1-overexpressing cells (Figure 7A). To elucidate the relationship
between EGFR and ERK activation, we used the specific inhibitor
AG1478 to block EGFR activation. Inhibition of EGFR
phosphorylation led to a simultaneous reduction in ERK
phosphorylation (Figure 7B), suggesting that EGFR activation is
responsible for downstream ERK phosphorylation.
We examined next whether EGFR-induced ERK activation
was responsible for the increased metastatic behaviors of LIV-1
overexpressing ARCaPE cells in transwell migration and invasion
assays. Blocking EGFR activation by AG1478 was accompanied
by reduced migratory and invasive capabilities (Figure 7C). In
support of these results, ERK inhibitor U0126 treatment also
reduced both the migratory and invasive capabilities (Figure 7D),
similar to AG1478 treatment. These results, taken together,
demonstrated that EGFR and downstream ERK activation is the
major signaling pathway stimulating the migratory and invasive
behavior of LIV-1 overexpressing cells.
LIV-1 activated EGFR signaling by increasing HB-EGF,
MMP2 and MMP9 expression
Since LIV-1 is a member of the ZIP metal transporters that may
regulate intracellular zinc ion homeostasis [1,5,28], we evaluated
whether the increased EGFR constitutive phosphorylation in LIV-
1 overexpressing clones was due to changes in intracellular zinc
concentration. Compared to the control clones, however, there
were no statistically significant differences in both the total zinc
determined by ICP-MS analysis and the labile fraction measured
by the fluorometric assay method (data not shown).
We then tested the hypothesis that as a result of activation of
EGFR in LIV-1 overexpressing cells, a positive feedback consisting
of an autocrine/paracrine loop of growth factors may be elicited to
account for increased tumorigenicity and metastatic potential. We
examined whether the increased EGFR phosphorylation was a
result of increased production of cognate ligands such as EGF and
HB-EGF proteins [29,30].
Western blotting revealed that LIV-1 overexpressing ARCaPE
clones and the control clones had similar levels of EGFR protein,
and upon ligand treatment both clones could be drastically
phosphorylated, which was abolished by specific inhibitor AG1478
Figure 5. LIV-1 overexpression promoted cancer bone and soft tissue metastasis. Upon intracardiac inoculation, ARCaPE clones
overexpressing LIV-1 caused metastatic tumor formation in athymic mice (Table 1). Representative results depict the metastatic tumors. A, a tibial
tumor (arrow) was identified by X-ray (Pathomorphology). The tumor was subjected to H&E staining for histopathologic confirmation. Compared to
the tibia of the opposite leg (Normal), the tibial tumor (Tumor) showed histopathology typical of a metastatic bone lesion. B, an adrenal gland
metastasis (held by forceps) destroyed the gland (Pathomorphology). Compared to the unaffected gland (Normal), tumor cells were found in every
part of the affected gland (Tumor) (250 6).
doi:10.1371/journal.pone.0027720.g005
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showed a constitutive EGFR phosphorylation in the absence of
exogenous ligand, and this phosphorylation could be abolished by
AG1478 treatment (Figure 8A). To investigate the cause of the
constitutive EGFR phosphorylation, we found while both of these
cell types produced low or undetectable levels of EGF by RT-
PCR, significantly increased levels of HB-EGF were expressed by
LIV-1 overexpressing clones compared to the control clones
(Figure 8B). These results indicated that HB-EGF may be a
constitutive inducer for EGFR signaling via increased EGFR
phosphorylation.
HB-EGF is synthesized as a membrane-anchored form which
needs to be released from the plasma membrane by matrix
metalloproteases (MMPs) in order to bind EGFR [31,32,33].
Interestingly, there was significantly higher MMP2 and MMP9
expression in the LIV-1-overexpressing clones (Figure 8B), while
gelatin zymography demonstrated that MMP2 and MMP9
enzymatic activities were also enhanced (Figure 8C). Importantly,
treatment with MMP2/9 inhibitor III led to a significant reduction
of soluble HB-EGF in the culture media as determined by ELISA
(Figure 8D), suggesting that these proteolytic enzymes were
involved in HB-EGF shedding. In other experiments, MMP2/9
inhibitor III treatment caused a time-dependent loss of phosphor-
ylation in both EGFR and the downstream ERK proteins
(Figure 8E), confirming that the proteolytic enzymes acted
upstream of EGFR-elicited MAPK signaling. Consequently,
MMP2/9 inhibition significantly reduced the migratory and
invasive ability of LIV-1-overexpressing cells in transwell assays
(Figure 8F). It seemed likely that the function of LIV-1 was to
stimulate the expression of MMP2, MMP9 and HB-EGF proteins,
which in turn activated EGFR and downstream ERK signaling,
leading to EMT that facilitated local tumor growth and its distant
metastases to bone and soft tissues (Figure 8G).
Discussion
Using the well-characterized ARCaP human prostate cancer
progression model, we found that LIV-1 is involved in the
promotion of prostate cancer cell EMT, local growth and distant
metastases. This conclusion is based on the following evidence: 1)
the induction of EMT by IGF-1 or TGF-b1 in ARCaPE cells was
accompanied by elevated LIV-1 expression (Figure 1A and 1B); 2)
LIV-1 expression was elevated in the isogenic cells expressing
mesenchymal phenotype, i.e. higher LIV-1 expression was found
in ARCaPM compared to ARCaPE cells (Figures 1C, 1E and 6A);
3) overexpression of LIV-1 in ARCaPE cells promoted irreversible
Figure 6. LIV-1 expression is associated with human prostate cancer progression. A, RT-PCR and Western blotting were used to determine
LIV-1 expression in different prostate cancer cell lines. b-actin was used as control in Western blotting and GAPDH was used as control for RT-PCR
analysis. B, representative IHC images showed increased LIV-1 expression in human prostate specimens from benign to bone metastasis (1256). C,
Interval plot of LIV-1 expression is shown versus prostate cancer progression from normal/benign, PIN, primary cancer to bone metastasis. The data
are shown with 95% confidence interval (n = number of cases analyzed). The median expression for LIV-1 in bone was significantly greater than in
normal/benign, PIN, and primary cancer (P,0.001) and in primary cancer only (P=0.002) as analyzed by Mann-Whitney test.
doi:10.1371/journal.pone.0027720.g006
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metastases to bone and soft tissues (Figures 3, 4, 5); 4) certain
EMT-inducing growth factors, such as b2-M, could both activate
LIV-1 expression and promote bone and soft tissue metastases in
prostate, breast, lung and renal cancer cells [26]; and 5) selected
repression of LIV-1 in ARCaPM cells was accompanied by a
reversal of EMT, causing ARCaPM to adopt a phenotype similar
to that of the ARCaPE cells with decreased migration and invasion
(Figure 1C and 1D). In addition, the function of LIV-1 in the
promotion of aggressive cancer behaviors is also supported by data
obtained from the analyses of a large number of clinical prostate
cancer specimens (Figure 6B and 6C).
Prostate cancer cells in metastasized tumors are known to
display both epithelial and mesenchymal phenotypes including
morphology and gene expression profiles, and metastatic prostate
tumors are likely comprised of heterogeneous populations of both
epithelial and mesenchymal cells. With regard to the mechanism
of interconversion between epithelial and mesenchymal pheno-
types through EMT and MET, it is interesting to note that
increased LIV-1 expression can be achieved by hormonal
induction [3,8] and by growth factor engagement (Figure 1). It
is conceivable that with induction of LIV-1, cancer cells can
establish metastatic foci through EMT that confers increased
migratory and invasive capabilities. Inside the tumor metastasis,
LIV-1 expression may subside once the inducer withdraws,
leading to tumor colonization with cancer cells resuming epithelial
morphology and biomarker expression.
Since LIV-1 overexpression was associated with the develop-
ment of larger prostate tumors (Figures 4 and 5) and with
accelerated proliferation in vitro (data not shown), we carried out
mechanistic analyses to elucidate the underlying regulatory
pathway. LIV-1 overexpressing clones expressed high levels of
Figure 7. LIV-1 overexpressing cells displayed constitutively activated EGFR signaling. A, LIV-1 overexpressing cells (LIV#8 and LIV#14)
showed increased phosphorylated EGFR (p-EGFR) and ERK (p-ERK). B, EGFR inhibitor (AG1478) treatment reduced phosphorylated EGFR and ERK in
LIV#8 clone. C, inhibition of EGFR suppressed migratory ability and invasive ability of LIV-1 overexpressing clones in transwell assays 24 hours after
treatment. D, inhibition of ERK signaling resulted in similar suppression of cellular motility as EGFR inhibition. * indicates statistical significance
compared to the control of the same group (P,0.05).
doi:10.1371/journal.pone.0027720.g007
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produced significantly increased MMP2 and MMP9 transcripts
(Figure 8B) as well as enzymatic activities (Figure 8C). The
enzymatic activities are involved in catalyzing HB-EGF shedding
(Figure 8D). The soluble form of HB-EGF may interact with
EGFR to cause constitutive EGFR phosphorylation (Figure 8E).
Figure 8. HB-EGF level and MMP2/9 activity were up-regulated in LIV-1 overexpressing cells. A, LIV-1 overexpressing cells (LIV#8) and
control cells (con1) were treated with EGF and AG1478 for 2 hours. Western blotting showed that the EGF-elicited EGFR and ERK phosphorylation was
blocked by the AG1478 inhibitor. B, RT-PCR showed increased HB-EGF, MMP2 and MMP9 expression in LIV-1 overexpressing cells. C, LIV-1
overexpressing cells (LIV#8 and LIV#14) were cultured in serum-free medium for 24 hours and the culture media were used to determine the MMP2
and MMP9 enzymatic activity by zymogram assay. D, the effect of MMP2/9 enzymatic activity on HB-EGF shedding was evaluated by ELISA. LIV-1
overexpressing clones (LIV#8 and LIV#14) secreted more HB-EGF than control clones (con1 and con2), and the secretion was reduced by MMP2/9
inhibition. * indicates statistical significance compared to the control of the group (P,0.05). E, Western blotting showed that inhibition of MMP2/9
activity suppressed EGFR and the downstream ERK phosphorylation. F, LIV-1 overexpressing cells were treated with MMP 2/9 inhibitor III for 24 hours
in Transwell motility assays. Both migration and invasion of the treated cells were decreased. * indicates statistical significance compared to the
control group (P,0.05). G, diagram depicts the proposed role of LIV-1 in prostate cancer cell EMT and metastasis.
doi:10.1371/journal.pone.0027720.g008
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duction, which favors cell growth and facilitates cellular motility.
In addition, ERK-mediated signaling may promote EMT by
downregulating E-cad expression, thus releasing b-catenin from
cytoplasmic membrane to enter the nucleus, where b-catenin
interacts with T cell-factor/lymphoid enhancer factor (LEF)
transcription factors to promote the growth and survival of cancer
cells [34].
The close correlation between LIV-1 level and cancer
progression documented in the clinical specimens is likely a
general phenomenon in prostate cancer. Several factors may
contribute to abnormally enhanced LIV-1 expression during
prostate cancer progression and metastasis. It has been shown that
LIV-1 expression is negatively regulated by intracellular zinc
concentration [1,5], which provides an auto-regulatory negative
feedback [1]. Prostate tumor cells are frequently observed with a
lowered intracellular zinc pool [17,35,36], which may induce LIV-
1 expression. Additionally, loss of intracellular zinc may prevent
cancer cells from apoptotic death, since a lowered zinc level can
alter mitochondrial membrane potential to hamper the release of
apoptosis-triggering caspases [37]. On the other hand, LIV-1
expression may also be stimulated by growth factors in the tumor
microenvironment, since treatment with TGFa, TGF-b1, EGF,
IGF-1 and b2-M all enhanced the LIV-1 level [3,4,27]. However,
no direct evidence shows that LIV-1 overexpression by genetic or
epigenetic mechanisms leads to cancer progression. We reported
recently that b2-M-mediated signaling could lead to a decreased
intracellular iron which drives EMT and cancer lethality to bone
and soft tissues [26]. Currently it is not clear if LIV-1 is involved in
an autoregulatory loop in the regulation of intracellular zinc and
iron. In this study, we did not find differences in intracellular total
zinc or labile zinc concentrations between LIV-1 overexpressed
and neo-control ARCaPE cells, suggesting that LIV-1 overexpres-
sion did not affect the intracellular zinc pool in prostate cancer
cells. Additional studies should be carried out to determine the role
of LIV-1 in determining zinc transport in other prostate cancer
cell lines.
Growth factor regulation by LIV-1 could be mediated by
STAT3 [15], which orchestrates the nuclear translocation of
several important pleiotropic transcription factors. LIV-1 was
shown to increase Snail transcription, translation and translocation
to cell nucleus in zebrafish [15]. Among many of the common
downstream transcription factors responsive to the pleiotropic
signals, Snail functions to drive EMT [38]. By directly repressing
E-cad transcription, Snail decreases cellular polarity and cell-cell
junction but promotes EMT not only in cancer cells, but also in
wound healing and renal fibrosis [7,18,19]. The relationship
between Snail and LIV-1 expression has been reported in breast,
cervical and pancreatic cancer progression and lymph node
metastases [8,12,13,14,39]. EMT plays a pivotal role in cell
motility during embryonic development [18,40], while breast
cancer cells undergoing EMT can gain stem cell-like properties
with increased ability for self renewal as determined by anchorage-
independent growth [41]. The link between EMT and stem cell-
like properties could have broader clinical implications for the
development of novel therapeutic approaches for cancer. The
pathophysiologic roles of LIV-1, however, may be cell context-
dependent as revealed in some breast cancer cell lines, LIV-1
expression has been associated with the suppression of E-cad,
while in others, LIV-1 knockdown paradoxically increased cancer
invasiveness [42].
Our results as described herein emphasize a coordinated
regulation of LIV-1 expression during prostate cancer cell EMT
which ultimately confers increased migratory, invasive and
metastastic potential. LIV-1 expression increased EGFR-ERK
signaling, through the shedding of HB-EGF from cell surface, by a
concomitant induction of MMP2 and MMP9 proteolytic enzymes,
which cleave the membrane-bound HB-EGF. The soluble HB-
EGF is responsible for EGFR phosphorylation and downstream
ERK signaling. Constitutive EGFR activation is a common
oncogenic signal in prostate cancer as well as in other
malignancies. Our study established for the first time a close link
between LIV-1 expression and EGFR-ERK signaling which drives
EMT and prostate cancer migration, invasion and metastases.
LIV-1 could be a new biomarker and a new therapeutic target for
prostate cancer progression and metastasis.
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